Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease by Winkler, Thomas W et al.
RESEARCH ARTICLE Open Access
Genome-wide association meta-analysis for
early age-related macular degeneration
highlights novel loci and insights for
advanced disease
Thomas W. Winkler1*† , Felix Grassmann2,3,4†, Caroline Brandl1,2,5, Christina Kiel2, Felix Günther1,6, Tobias Strunz2,
Lorraine Weidner1, Martina E. Zimmermann1, Christina A. Korb7, Alicia Poplawski8, Alexander K. Schuster7,
Martina Müller-Nurasyid8,9,10,11, Annette Peters12,13, Franziska G. Rauscher14,15, Tobias Elze14,16, Katrin Horn14,15,
Markus Scholz14,15, Marisa Cañadas-Garre17, Amy Jayne McKnight17, Nicola Quinn17, Ruth E. Hogg17,
Helmut Küchenhoff6, Iris M. Heid1†, Klaus J. Stark1† and Bernhard H. F. Weber2,18†
Abstract
Background: Advanced age-related macular degeneration (AMD) is a leading cause of blindness. While around half of the
genetic contribution to advanced AMD has been uncovered, little is known about the genetic architecture of early AMD.
Methods: To identify genetic factors for early AMD, we conducted a genome-wide association study (GWAS) meta-analysis
(14,034 cases, 91,214 controls, 11 sources of data including the International AMD Genomics Consortium, IAMDGC, and UK
Biobank, UKBB). We ascertained early AMD via color fundus photographs by manual grading for 10 sources and via an
automated machine learning approach for > 170,000 photographs from UKBB. We searched for early AMD loci via GWAS
and via a candidate approach based on 14 previously suggested early AMD variants.
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Results: Altogether, we identified 10 independent loci with statistical significance for early AMD: (i) 8 from our GWAS with
genome-wide significance (P < 5 × 10− 8), (ii) one previously suggested locus with experiment-wise significance (P < 0.05/
14) in our non-overlapping data and with genome-wide significance when combining the reported and our non-
overlapping data (together 17,539 cases, 105,395 controls), and (iii) one further previously suggested locus with experiment-
wise significance in our non-overlapping data. Of these 10 identified loci, 8 were novel and 2 known for early AMD. Most of
the 10 loci overlapped with known advanced AMD loci (near ARMS2/HTRA1, CFH, C2, C3, CETP, TNFRSF10A, VEGFA, APOE),
except two that have not yet been identified with statistical significance for any AMD. Among the 17 genes within these
two loci, in-silico functional annotation suggested CD46 and TYR as the most likely responsible genes. Presence or absence
of an early AMD effect distinguished the known pathways of advanced AMD genetics (complement/lipid pathways versus
extracellular matrix metabolism).
Conclusions: Our GWAS on early AMD identified novel loci, highlighted shared and distinct genetics between early and
advanced AMD and provides insights into AMD etiology. Our data provide a resource comparable in size to the existing
IAMDGC data on advanced AMD genetics enabling a joint view. The biological relevance of this joint view is underscored
by the ability of early AMD effects to differentiate the major pathways for advanced AMD.
Keywords: Genome-wide association study (GWAS), Meta-analysis, Age-related macular degeneration (AMD), Early
AMD, CD46, TYR, International AMD genomics consortium (IAMDGC), UK biobank (UKBB), Machine-learning, Automated
phenotyping
Background
Age-related macular degeneration (AMD) is the leading
cause of irreversible central vision impairment in in-
dustrialized countries. Advanced AMD presents as
geographic atrophy (GA) and/or neovascular (NV)
complications [1]. Typically, advanced AMD is pre-
ceded by clinically asymptomatic and thus often
unrecognized early disease stages. Early AMD is char-
acterised by differently sized yellowish accumulations
of extracellular material between Bruch’s membrane
and retinal pigment epithelium (RPE) or between RPE
and the photoreceptors (drusen or subretinal druse-
noid deposits, respectively). Other features of early
AMD are RPE abnormalities, including depigmen-
tation or increased amount of pigment [1].
Early and advanced AMD can be documented by color
fundus imaging of the central retina and/or other multi-
modal imaging approaches including optical coherence
tomography (OCT) [1–3]. While the definition of ad-
vanced AMD is reasonably homogeneous across clinical
and epidemiological studies, the classification of early
AMD is more variable and different studies traditionally
apply differing classification systems [4, 5].
Epidemiological studies show that high age is the
strongest risk factor for early and advanced AMD onset
as well as progression [1, 6–8]. A robust genetic influ-
ence was shown for advanced AMD [1, 9–11] with 34
distinct loci at genome-wide significance in a large
genome-wide association study (GWAS) for advanced
AMD [9]. The genes underneath these advanced AMD
loci were found to be enriched for genes in the alterna-
tive complement pathway, HDL transport, and extracel-
lular matrix organization and assembly [9].
Exploring the genetics of early AMD offers the potential
to understand the mechanisms of early disease processes,
but also for the development to advanced AMD when com-
paring genetic effect sizes for early and advanced stages.
Yet there have been few published GWAS searches for
early AMD. One meta-analysis on 4089 early AMD patients
and 20,453 control persons reported two loci with genome-
wide significance, both being well known from advanced
AMD, the CFH and the ARMS2/HTRA1 locus [12].
We have thus set out to gather GWAS data for early
AMD from 11 sources including own study data, data
from the International AMD Genomics Consortium
(IAMDGC), dbGaP and UK Biobank to conduct the
largest GWAS meta-analysis on early AMD to date.
Methods
GWAS data from 11 sources
We included 11 sources of data with GWAS data and
color fundus photography for early AMD phenotyping
(Table S1). Our studies were primarily population-based
cohort studies, where the baseline survey data were used
for this analysis from studies of the authors (GHS, LIFE,
NICOLA, KORA, AugUR) as well as for publicly available
studies from dbGaP (ARIC, CHS, WHI; accession numbers:
phs000090.v5.p1, phs000287.v6.p1, phs000746.v2.p3). We
also included data from UK Biobank for participants from
baseline and additional participants from the follow-up sur-
vey, since the color fundus photography program had
started only after the main study onset (application number
#33999). The studies captured an age range from 25 to 100
years of age (mean age from 47.5 years to 77.2 years across
the 10 population-based studies, AugUR with the very old
individuals range from 70.3 years to 95 years). About 50%
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of the study participants in each study were male (except
for the Women’s Health Initiative, WHI), and all demon-
strated European ancestry. All studies (except GHS-1,
GHS-2 and Life-Adult) excluded any person with at least
2nd degree relationship (Table S1). For each of these cross-
sectional data sets, participants with at least one eye grad-
able for AMD (see below) and with existing GWAS data
were eligible for our analysis. We excluded participants
with advanced AMD. We used participants with ascer-
tained early AMD as cases and participants being ascer-
tained for not having any signs of AMD as controls (n =
7363 cases, 73,358 controls across these population-based
studies). Case-control data were also included from IAMD
GC (http://amdgenetics.org/). The early AMD GWAS from
IAMDGC is based on 24,527 individual participant data
from 26 sources [9]. This data includes 17,856 participants
with no AMD and 6671 participants with early AMD (ex-
cluding the 16,144 participants with advanced AMD). The
cases and controls from IAMDGC were 16 to 102 years of
age (mean age = 71.7 years). For all of these participants,
DNA samples had been gathered and genotyped centrally
(see below) [9].
Genotyping and imputation
All population-based studies were genotyped, quality
controlled and imputed using similar chip platforms and
imputation approaches (Table S2). As the imputation
backbone, the 1000 Genomes Phase 1 or Phase 3 refer-
ence panel was applied [13], except GHS was imputed
based on the Haplotype Reference Consortium (HRC)
[14] and UK Biobank was imputed based on HRC and
the UK10K haplotype resource [15]. Details on the UK
Biobank genotypic resource are described elsewhere
[16]. For the IAMDGC case-control data, DNA samples
had been gathered across all participants and genotyped
on an Illumina HumanCoreExome array and quality
controlled centrally. Genotype quality control and im-
putation to the 1000 Genomes phase 1 version 3 refer-
ence panel (> 12 million variants) were conducted
centrally. Details on the IAMDGC data were described
in detail by Fritsche et al. [9].
Phenotyping
Across all studies included into this analysis, early AMD
and the unaffected status was ascertained by color fun-
dus photography. For participants from AugUR and
LIFE, “early AMD” was classified according to the Three
Continent Consortium (3CC) Severity Scale [4], which
separates “mild early” from “moderate” and “severe
early” AMD stages depending on drusen size, drusen
area, or the presence of pigmentary abnormalities [4].
For the analysis, we collapsed any of these “early” AMD
stages into the definition of “early AMD”. However, the
3CC Severity Scale was not available for the other
studies. In these, similar early AMD classifications, con-
sidering drusen size or area and presence of pigmentary
abnormalities, were used (Table S1): For participants
from GHS, the Rotterdam Eye Study classification was
applied [17]. For participants from NICOLA, the Beck-
man Clinical Classification was utilized [18]. Participants
from the KORA study were classified as “early AMD”
based on the AREDS-9 step classification scheme and
we defined “early AMD” for this analysis by AREDS-9
steps 2–8 [19]. The ascertainment of IAMDGC study
participants is described in detail elsewhere and covers
various classification systems [9]. Of note, LIFE and
NICOLA phenotyping incorporated OCT information
additional to the information from color fundus imaging
(Table S1). For UK Biobank participants, color fundus
images were received (application number 33999); there
was no existing AMD classification available in UK Bio-
bank (see below). The AMD status of a person was de-
rived based on the AMD status of the eye with the more
severe AMD stage (“worse eye”) when both eyes were
gradable, and as the grade of the one available eye other-
wise. Eyes were regarded as gradable, if at least one
image of the eye fulfilled defined quality criteria allowing
for the assessment of AMD (bright image, good color
contrast, full macular region captured on images). Im-
ages were excluded from AMD grading if they revealed
obscuring lesions (e.g. cataract) or lesions considered to
be the result of a competing retinal disease (such as
advanced diabetic retinopathy, high myopia, trauma,
congenital diseases, or photocoagulation unrelated to
choroidal neovascularization). Details for IAMDGC are
described previously [9]. Persons with gradable images
for at least one eye were included in this analysis.
Persons with advanced AMD defined as presence of
neovascularization or geographic atrophy in at least one
eye were excluded for the main GWAS on early AMD.
Automated classification of early AMD in UK biobank
To obtain early AMD phenotype data for UK Biobank
participants, we used a pre-trained algorithm for auto-
mated AMD classification based on an ensemble of con-
volutional neural networks [20]. In the UKBB baseline
data, fundus images were available for 135,500 eyes of
68,400 individuals with at least one image. Among the
additional 38,712 images of 19,501 individuals in the
follow-up, there were 17,198 individuals without any
image from baseline. For each image (eye) at baseline
and follow-up, we predicted the AMD stage on the
AREDS-9 step severity scale using the automated AMD
classification. We defined a person-specific AMD stage
at baseline and follow-up based on the worse eye. Eyes
that were classified as ungradable were treated as miss-
ing data and, if diagnosis was available for only one eye,
the person-specific AMD stage was based on the
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classification of the single eye. If we obtained an auto-
mated disease classification to an AMD stage (i.e. not
“ungradable” for both eyes) at baseline and follow-up,
we used the follow-up disease stage (and follow-up age)
in the association analysis. By this, we obtained an auto-
mated AMD classification for 70,349 individuals (2161
advanced AMD, 3835 early AMD, 64,353 unaffected).
Individuals with advanced AMD were excluded from
this analysis. Finally, we yielded 57,802 unrelated indi-
viduals of European ancestry with valid GWAS data that
had either early AMD or were free of any AMD (3105
cases, 54,697 controls). We evaluated the performance
of the automated disease classification by selecting 2013
individuals (4026 fundus images) for manual classifica-
tion based on the 3CC Severity Scale. Details are de-
scribed elsewhere [21]. We found reasonable agreement
between the automated and the manual classification for
the four categories of “no AMD”, “early AMD”, “ad-
vanced AMD” and “ungradable” (concordance = 79.5%,
Cohen’s kappa κ = 0.61, kappa with list-wise exclusion of
ungradable individuals κ = 0.47 [22]). We found 305 of
the 2013 individuals to be ungradable by the automated
approach (i.e. 15.2%), including 257 individuals that have
also been ungradable manually (i.e. truly bad image
quality for both eyes) and 48 individuals that had been
manually gradable, but not with the automated approach
(i.e. 2.4%). Further details and further comparisons are
provided in the Supplementary Note and Tables S3-S4.
Study-specific association analyses
Study-specific logistic regression analyses (early AMD
cases versus controls, excluding advanced AMD cases)
were applied by study partners (in Regensburg, Leipzig,
Mainz, Belfast) using an additive genotype model and
according to a pre-defined analysis plan. All publicly
available data from dbGAP (studies ARIC, CHS and
WHI) and UK Biobank as well as IAMDGC data was an-
alyzed in Regensburg. All studies inferred the association
of each genetic variant with early AMD using a Wald
test statistic as implemented in RVTESTS [23]. Age and
two principal components (to adjust for population
stratification) were included as covariates in the regres-
sion models. We conducted sensitivity analyses to evalu-
ate the impact of additionally including sex and 10
principal components in the regression models on the
example of the two largest data sets, the IAMDGC and
the UKBB data. The IAMDGC analyses were further ad-
justed for DNA source as done previously [9]. For the
IAMDGC data that stemmed from 26 sources, we con-
ducted a sensitivity analysis additionally adjusting for
source membership according to previous work highlight-
ing slight differences in effect estimates [24]; we found the
same results.
Quality control of study-specific aggregated data
GWAS summary statistics for all data sources were
processed through a standardized quality-control (QC)
pipeline [25]. This involved QC checks on file complete-
ness, range of test statistics, allele frequencies, population
stratification as well as filtering on low quality data. We
excluded variants with low minor allele count (MAC< 10,
calculated as MAC = 2*Neff*MAF, with Neff being the ef-
fective sample size, Neff = 4NCases*NControls/(NCases + NCon-
trols) and MAF being the minor allele frequency), low
imputation quality (rsq < 0.4) or large standard error of
the estimated genetic effect (SE > 10). Genomic control
(GC) correction was applied to each GWAS result to cor-
rect for population stratification within each study [26].
The estimation of the GC inflation factor was based on
variants outside of the 34 known advanced AMD regions
(excluding all variants within < 5Mb base positions to any
of the 34 known advanced AMD lead variants). The GC
factors ranged from 1.00 to 1.04 (Table S2). We trans-
ferred all variant identifiers to unique variant names con-
sisting of chromosomal, base position (hg19) and allele
codes in (e.g. “3:12345:A_C”, allele codes in ASCII ascend-
ing order).
GWAS meta-analysis across the 11 sources of data for
early AMD genetics
For signal detection and effect quantification, study-
specific genetic effects were combined using an inverse-
variance weighted fixed effect meta-analysis method as
implemented in METAL [27]. We performed additional
QC on meta-analysis results: We only included variants
for identification that were available (i) in at least two of
the 11 data sources with a total effective sample size of
more than 5000 individuals (Neff > 5000) and (ii) for
chromosome and position annotation in dbSNP (hg19).
A conservative second GC correction (again focusing on
variants outside the known advanced AMD regions) was
applied to the meta-analysis result, in order to correct
for potential population stratification across studies [26].
The GC lambda factor of the meta-analysis was 1.01.
Genome-wide search for early AMD variants, variant
selection, and locus definition
In our first approach, we conducted a genome-wide
search for variants associated with early AMD and
judged at a genome-wide significance level (P < 5.0 ×
10− 8). Variants identified by this GWAS approach were
deemed as established with genome-wide significance in
our meta-analysis (tier 1). To evaluate the robustness of
any novel genome-wide significant AMD locus, we per-
formed leave-one-out (LOO) meta-analyses. We also
evaluated heterogeneity between study-specific genetic
effect estimates for selected variants using the I2 mea-
sures [28–30].
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We combined genome-wide significant variants (P <
5.0 × 10− 8) into independent loci by using a locus definition
similar to what was done previously [9]: the most significant
variant was selected genome-wide, all variants were ex-
tracted that were correlated with this lead variant (r2 > 0.5,
using IAMDGC controls as reference) and a further 500 kb
were added to both sides. All variants overlapping the so-
defined locus were assigned to the respective locus. We
repeated the procedure until no further genome-wide sig-
nificant variants were detected. Genes overlapping the so-
defined loci were used for biological follow-up analyses
(gene region defined from start to end). To identify inde-
pendent secondary signals at any novel AMD locus, ap-
proximate conditional analyses were conducted based on
meta-analysis summary statistics using GCTA [31].
Candidate approach
Additionally to the genome-wide search in our meta-
analysis of 14,034 cases and 91,214 controls, we adopted
a candidate approach based on the 14 reported suggest-
ive variants by Holliday et al. (P-values from 8.9 × 10− 6
to 1.1 × 10− 6 in their meta-analysis, 4089 cases and 20,
453 controls) [12]. For this, we analyzed our data with-
out the studies that overlapped with the previously re-
ported data (i.e. removing ARIC, CHS; yielding 13,450
cases and 84,942 controls). We also combined the data
from Holliday et al. with this non-overlapping part of
our data where possible (i.e. the 14 reported variants) by
an inverse-variance weighted meta-analysis (altogether
17,539 cases, 105,395 controls). We judged these 14 vari-
ants’ association at experiment-wise significance (P <
0.05/14) in our non-overlapping data and at genome-
wide significance (PCombined < 5.0 × 10
− 8) in the com-
bined analysis. We considered a candidate-based se-
lected variant as established with both experiment-wise
significance (P < 0.05/14 in our non-overlapping data)
and with genome-wide significance (PCombined < 5.0 ×
10− 8 in the combined data) (tier 2), or as established
with experiment-wise significance (P < 0.05/14 in our
non-overlapping data), but without established genome-
wide significance (PCombined ≥ 5.0 × 10
− 8) (tier 3).
Gene prioritization at newly identified AMD loci
To prioritize genes and variants at the newly identified
AMD loci, we conducted a range of statistical and func-
tional follow-up analyses. The following criteria were used:
(1) Statistical evidence; we computed the posterior prob-
ability of each variant using Z-scores and derived 95%
credible intervals for each locus [32]. The method assumes
a single causal signal per locus. (2) Variant effect predictor
(VEP) to explore whether any of the credible variants was
located in a relevant regulatory gene region [33]. (3) eQTL
analysis: We downloaded expression summary statistics
for the candidate genes in retina from the EyeGEx
database [34] and for 44 other tissues from the GTEx
database [35] (both available at www.gtexportal.org/home/
datasets) and evaluated whether any of the credible vari-
ants showed significant effects on expression levels in the
aggregated data. For each significant eQTL in EyeGEx, we
conducted colocalization analyses using eCAVIAR [36] to
evaluate whether the observed early AMD association sig-
nal colocalized with the variants’ association with gene ex-
pression. (4) Retinal expression: We queried the
EyeIntegration database to evaluate genes in the relevant
loci for expression in fetal or adult retina or RPE cells
[37]. (5) Animal model: We queried the Mouse Genome
Informatics (MGI) database (www.informatics.jax.org) for
each gene in the relevant loci for relevant eye phenotypes
in mice [38]. (6) Human phenotype: The Online Mendel-
ian Inheritance in Man (OMIM)® database was queried for
human eye phenotypes (McKusick-Nathans Institute of
Genetic Medicine, Johns Hopkins University, Baltimore,
MD, queried 07/11/2019, www.omim.org).
Phenome-wide association study for newly identified
AMD loci
We used 82 other traits and queried reported genome-
wide significant (P < 5.0 × 10− 8) lead variants and proxies
(r2 > 0.5) for any of these traits for overlap with genes
underneath our novel loci as done previously [39]. For
this, we used GWAS summary results that were previ-
ously aggregated from GWAS catalogue [40], GWAS
central [41] and literature search.
For the novel early AMD lead variants, we further evalu-
ated their association with 118 non-binary and 660 binary
traits from the UK Biobank [42]. The Phenome-wide associ-
ation study (PheWAS) web browser “GeneATLAS” (www.
geneatlas.roslin.ed.ac.uk) was used for the UK Biobank
lookup. For each variant, association P values were corrected
for the testing of multiple traits by the Benjamini-Hochberg
false-discovery-rate (FDR) method [43].
Interaction analyses
For the novel early AMD effects and for the 34 known
advanced AMD lead variants [9], we investigated
whether age modulated early AMD effects by analyzing
variant x age interaction in seven data sources for which
we had individual participant data available in Regens-
burg (ARIC, CHS, WHI, IAMDGC, UKBB, AugUR and
KORA). For each source, we applied logistic regression
and included a variant x AGE interaction term in the
model (in addition to the covariates used in the main
analysis). We conducted meta-analysis across the seven
sources to obtain pooled variant x age interaction effects
and applied a Wald test to test for significant interaction
(at a Bonferroni-corrected alpha-level). For the novel
early AMD effects, we further investigated whether age
modulated advanced AMD effects by evaluating
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publically available data from IAMDGC [44]. Finally, we
investigated whether a novel early AMD lead variant
modulated any of the effects of the 34 known AMD vari-
ants on advanced AMD [9]. We used the IAMDGC data
and applied one logistic regression model for each pair
of known advanced AMD variants and novel early AMD
variants including the two respective variants and their
interaction (and the same other covariates as before).
Comparison of genetic effects on early and advanced
stage AMD
We estimated the genetic correlation between early and ad-
vanced AMD by utilizing the LDSC tool [45] with the
GWAS summary statistics for early and advanced AMD
(from the current meta-analysis and the IAMDGC [9], re-
spectively). We used pre-calculated LD scores for European
ancestry (https://data.broadinstitute.org/alkesgroup/
LDSCORE/eur_w_ld_chr.tar.bz2). We further compared
genetic effect sizes between early and advanced AMD for
the novel early AMD lead variants and for the 34 known
advanced AMD lead variants [9]. For this, we queried the
novel early AMD lead variants in the IAMDGC GWAS for
advanced AMD [9] and (vice-versa) queried the 34 known
advanced AMD lead variants [9] in the early AMD meta-
analysis results. We compared effect sizes in a scatter plot
and clustered the lead variants by their nominal significant
association on advanced and/or early AMD. We classify dif-
ferent types of loci in a similar fashion as done previously
for adiposity trait genetics [46]: (1) “advanced-and-early”
AMD loci (Pearly < 0.05, Padv < 0.05), (2) “advanced-only”
AMD loci (Pearly ≥ 0.05, Padv < 0.05), (3) “early-only” AMD
loci (Pearly < 0.05, Padv ≥ 0.05).
Pathway analysis
To evaluate whether “advanced-and-early” AMD loci versus
“advanced-only” AMD loci distinguished the major known
pathways for advanced AMD, we performed pathway en-
richment analysis separately for these two classes. We used
the genes in the gene prioritization for all advanced AMD
loci as previously described [9], derived the gene
prioritization score and selected the best scored gene in
each locus (two genes in the case of ties). We then sepa-
rated the gene list according to the class of the respective
locus, and performed pathway enrichment analysis via
Enrichr [47] with default settings searching Reactome’s cell
signaling pathway database 2016 (n = 1530 pathways). P-
values were corrected for multiple testing with Benjamini-
Hochberg procedure [43].
Results
Eight genome-wide significant loci from a GWAS on early
AMD
We conducted a meta-analysis of genotyped and im-
puted data from 11 sources (14,034 early AMD cases,
91,214 controls; 11,702,853 variants; for study-specific
genotyping, analysis and QC, see Tables S1-S2). For all
participants, early AMD or control status (i.e. no early
nor late AMD) was ascertained via color fundus photo-
graphs (Table S1). This included automated machine-
learning based AMD classification of UK Biobank fun-
dus images (application number 33999; 56,699 individ-
uals from baseline, 13,650 additional individuals from
follow-up) [16, 20]. Based on logistic regression associ-
ation analysis in each of the 11 data sets meta-analyzed
via fixed effect model, we identified eight distinct loci
with genome-wide significance (tier1; P = 1.3 × 10− 116 to
4.7 × 10− 8, Fig. 1, Table 1; “locus” defined by the lead
variant and proxies, r2 ≥ 0.5, +/− 500 kb). Six of these
loci were novel for early AMD; two loci had been identi-
fied for early AMD previously [12].
Most of the eight loci overlap with known loci for ad-
vanced AMD [9] (CFH, ARMS2/HTRA1, C2, C3, CETP,
VEGFA, TNFRSF10A), except one which has not been
identified in early or advanced AMD GWAS before (P =
4.7 × 10− 8, lead variant rs4844620, near CD46, Figure
S1). This novel locus around rs4844620 (near CD46) is
independent of known (advanced) AMD loci: rs4844620
is (i) ~ 500 K base positions distant from the recently re-
ported AMD locus near C4BPA/CD55 [11] and uncorre-
lated to the reported C4BPA/CD55 lead variant
rs11120691 (r2 < 0.01) and (ii) > 10 million base posi-
tions distant from the CFH locus and uncorrelated to
any of the eight reported CFH locus variants, r2 < 0.01).
Taken together, we identified eight loci for early
AMD, two known for early AMD and six novel, includ-
ing one novel locus (near CD46) for any AMD with
genome-wide significance.
Two further significant loci from a candidate-based
approach of 14 variants
Subsequently, we applied a candidate-based approach by
investigating the 14 variants reported as suggestive by
the previous GWAS for early AMD (4089 early AMD
cases, 20,453 controls; reported P between 1.1 × 10− 6
and 8.9 × 10− 6) [12]. For this, we re-analyzed our data
excluding the overlap with the previous GWAS (i.e. ex-
cluding ARIC, CHS study, yielding 13,450 early AMD
cases and 84,942 controls) and also combined the re-
ported and our non-overlapping data in an inverse-
variance weighted meta-analysis where possible (i.e. for
the 14 reported variants; altogether 17,539 cases, 105,
395 controls). Among the 14 variants, we found four sig-
nificant variants for early AMD (Table 2): (i) two “tier 2”
variants (near PVRL2 and CD46) with experiment-wise
significance (P < 0.05/14) in our non-overlapping data
and with genome-wide significance (PCombined < 5.0 ×
10− 8) in the combined analysis, and (ii) two additional
“tier 3” variants (near APOE/TOMM40 and TYR) with
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experiment-wise significance (P < 0.05/14) in our non-
overlapping data.
We compared the evidence from the Bonferroni-
corrected analysis judged at experiment-wise significance
and the combined analysis judged at genome-wide sig-
nificance. Both “tier 3” variants showed combined P-
values close to the genome-wide significant threshold
(PCombined = 9.0 × 10
− 8 and 1.7 × 10− 7, for the APOE/
TOMM40 and the TYR variant, respectively), while the
other 10 of the 14 variants showed combined P-values
far away from significance (Pcombined from 4.8 × 10
− 3 to
0.74). Therefore, the Bonferroni-corrected analysis and
the combined analysis yielded similar evidence and sepa-
rated the 14 suggested variants into four variants with a
positive finding (near CD46, PVRL2, APOE/TOMM40
and TYR) from the 10 variants with no finding (P > 0.05
in our non-overlapping data, Table 2).
Two of the four identified variants were correlated: the
tier3-identified variant rs2075650 near APOE/TOMM40
was located in the same locus as the tier2-identified vari-
ant rs6857 near PVRL2 (r2 = 0.75 to rs2075650) and thus
counted as one locus (near APOE/TOMM40/PVRL2).
The tier2-identified variant rs1967689 near CD46 was
located in one of the eight loci identified by our GWAS
(r2 = 0.77 to our GWAS lead variant rs4844620). The
two other loci (near APOE/TOMM40/PVRL2 and TYR)
were identified in addition to our GWAS. These two loci
were identified here for the first time with statistical sig-
nificance as loci for early AMD: one locus known for ad-
vanced AMD (near APOE) and one identified here for
Fig. 1 Early AMD meta-analysis. Shown are the association results of the meta-analysis for early AMD: a by their position on the genome
(Manhattan plot) with color indicating whether the locus was previously identified by Holliday et al. [12] (blue), novel for early AMD (red), or
among the other advanced AMD loci identified by Fritsche et al. [9] (green); and b their distribution (QQ plot)
Table 1 Genome-wide search for early AMD association
Rs identifier chr:pos [hg19] EA OA EAF logOR SE OR P N cases N controls Known advanced
AMD locus (Fritsche et al.)
Locus name
Novel early AMD loci:
rs4844620 1:207980901 g a 0.79 0.095 0.017 1.10 4.7E-08 14,031 91,179 no CD46
rs547154 6:31910938 g t 0.91 0.218 0.025 1.24 1.3E-18 14,027 91,137 yes C2
rs943080 6:43826627 t c 0.51 0.080 0.015 1.08 4.7E-08 13,220 85,747 yes VEGFA
rs13278062 8:23082971 t g 0.52 0.080 0.014 1.08 2.0E-08 13,644 85,908 yes TNFRSF10A
rs5817082 16:56997349 c ca 0.26 0.108 0.017 1.11 1.0E-10 12,599 81,863 yes CETP
rs11569415 19:6716279 a g 0.21 0.116 0.018 1.12 1.7E-10 13,115 83,117 yes C3
Known early AMD loci:
rs4658046 1:196670757 c t 0.39 0.321 0.014 1.38 2.9E-114 14,034 91,201 yes CFH
rs3750847 10:124215421 t c 0.22 0.384 0.017 1.47 1.3E-116 14,025 91,171 yes ARMS2/HTRA1
EA effect allele, OA other allele, EAF effect allele frequency, logOR log odds ratio, SE standard error of logOR; OR odds ratio, P double GC corrected early
association P value from the meta-analysis
The table shows the eight genome-wide significant (P < 5.0 × 10− 8) lead variants from the early AMD meta-analysis. The second last column indicates whether the
locus was identified by Fritsche et al. for advanced AMD [9]
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the first time for any AMD with statistical significance
(rs621313, near TYR, P = 6.8 × 10− 4, Figure S2).
Together with our GWAS approach, we identified 10
independent loci with statistical significance for early
AMD: (i) eight from our GWAS (P < 5.0 × 10− 8 in our
meta-analysis, tier 1), (ii) one additional from the candi-
date approach with experiment-wise and with genome-
wide significance (tier 2), and (iii) one additional from the
candidate approach with experiment-wise significance
(tier 3). Among the 10 identified loci (any tier), two were
reported previously for early AMD (near CFH, ARMS2/
HTRA1) and eight were identified here for the first time
for early AMD with statistical significance (near CD46,
C2, C3, CETP, TNFRSF10A, VEGFA, APOE/TOMM40/
PVRL2 and TYR). The eight loci included two that have
not previously been identified with statistical significance
for any AMD (near CD46 and TYR). These two loci
showed no second signals (GCTA [31], PCond > 5.0 × 10
− 8
for CD46 and PCond > 0.05/14 for TYR, Figure S1-2).
Sensitivity analysis on the 10 identified early AMD loci
We conducted various sensitivity analyses to evaluate the
robustness of the associations for the 10 identified lead vari-
ants: (a) leaving out one of the 11 data sets at a time
showed similar effect estimates in most cases, except for
the exclusion of the two largest contributing sources,
IAMDGC and UKBB, which had the strongest impact on
effect sizes due to their relatively large sample size (Figure
S3). Exclusion of IAMDGC slightly increased the CD46 ef-
fect size (due to a slightly smaller effect in IAMDGC, Figure
S3A), had no impact on the TYR effect size (Figure S3B),
and decreased effect sizes for C2, CETP, C3, APOE, CFH
and ARMS2/HTRA1 variants (due to a relatively large asso-
ciation in IAMDGC). Exclusion of UKBB had no impact on
the CD46 variant effect (Figure S3A), slightly diminished
the TYR effect (due to a relatively strong effect in UKBB,
Figure S3B) and increased effect sizes near C2, C3 or CFH.
(b) Between-study heterogeneity in our meta-analysis was
similar to the heterogeneity in any of the leave-one-out
meta-analyses, which indicated that the observed hetero-
geneity was not driven by one single data set (Table S5).
We observed low to moderate between-study heterogeneity
[28] for the two novel any AMD loci (I2 between 22 to
48.3% and 45.4 to 63.8% for the TYR and CD46 lead vari-
ant, respectively). (c) Effect sizes were robust to additional
adjustment for sex or inclusion of additional genetic princi-
pal components in the regression analyses (Figure S4). In
the following, we were particularly interested in fine-
mapping the two loci that have not been identified before
for any AMD: the loci near CD46 and TYR.
Gene prioritization at the two novel loci
To prioritize variants and genes at the CD46 and TYR
locus, we conducted in silico follow-up analyses for all
variants and overlapping genes for each of these two loci
(4451 or 5729 variants, 10 or 7 genes, respectively). We
found several interesting aspects (Table 3): (1) When
prioritizing variants according to their statistical evi-
dence for being the driver variant by computing 95%
credible sets of variants [32], we found 23 and 294 cred-
ible set variants for the CD46 and TYR locus, respect-
ively (Table S6). (2) Using the Variant Effect Predictor
[33], we assessed overlap of credible set variants with
functional regulatory regions and found variants influen-
cing the transcript and/or the protein for four genes
(Table S7): variants causing an alternative splice form
for CD46, a nonsense-mediated mRNA decay (NMD)
for CR1L, a missense variant for TYR (rs1042602, r2 =
0.56 to the lead variant rs621313), and NMD variants for
NOX4. (3) We investigated credible set variants for being
an expression quantitative trait locus (eQTL) for any of
the 17 genes in retina (Eye Genotype Expression data-
base, EyeGEx [34]) or in 44 other tissues (Genotype-Tis-
sue Expression database, GTEx [35]). For the CD46
locus, we observed significant association of the lead
variant and additional 16 credible set variants on CD46
expression in retina (FDR < 5%, Table S8); the early
AMD risk increasing alleles of all 17 variants were asso-
ciated with elevated CD46 expression. Importantly, we
observed the expression signal to colocalize with the
early AMD association signal using eCAVIAR [36] (3
variants with colocalization posterior probability CLPP>
0.01, Table S9, Figure S5-S6). We also found credible
variants to be associated with CD46 expression in 15
other tissues from GTEx, including four brain tissues
(FDR < 0.05, Table S10). Among the credible set variants
in the two loci, we found no further eQTL for any of the
other genes. When extending beyond the credible set,
we found one further CD46 locus variant as eQTL for
CD55, but without colocalization (Table S9, Figure S5-
S6). These findings support the idea that the credible set
captures the essential signal. (4) We queried the 17
genes overlapping the two loci for expression in eye tis-
sue and cells in EyeIntegration summary data [37]. We
found five and three genes, respectively, expressed in
adult retina and adult RPE cells (CD46, PLXNA2, CR1,
CD34, CD55; TYR, GRM5, NOX4; Figure S7-S8). (5)
When querying the 17 genes in the Mouse Genome In-
formatics, MGI [38] or Online Mendelian Inheritance in
Man, OMIM®, database, for eye phenotypes in mice or
humans, we identified relevant eye phenotypes for five
genes in mice (CD46, CR1, CR1L, PLXNA2; TYR; Table
S11) and for one gene in human (TYR; Table S12).
While it is debatable how to prioritize evidence for a
gene’s probability to be causal, one approach is to count
any of the following characteristics for each of the 17
genes (Gene Prioritization Score, GPS Table 3): any
credible set variant is (i) protein-coding, (ii) involved in
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NMD, (iii) affecting splice function, (iv) an eQTL for this
gene in retina (EyeGEx) or in any other tissue (GTEx),
or/and the gene (v) is expressed in retina or RPE, (vi)
linked to eye phenotype in mouse or (vii) human.
This approach offered CD46 and TYR as the highest
scored gene in the respective locus (GPS = 4 for each;
Table 3).
Phenome-wide association search for the two novel loci
Co-association of variants in the two novel loci for early
AMD with other traits and diseases may provide insights
into shared disease mechanisms. We queried different
data sets on numerous phenotypes by a gene-based and
by a locus-based view.
For the gene-based view, we focused on 82 traits and
evaluated reported genome-wide significant (P < 5.0 ×
10− 8) lead variants (and proxies, r2 > 0.5) for overlap
with any of the 17 gene regions (Table S13). For the
CD46 locus, we found significant association corrected
for multiple testing (false-discovery rate, FDR < 5%) for
schizophrenia (in CD46 and CR1L) and for Alzheimer’s
disease (in CR1, Table S14). For the TYR locus, we
found significant associations for eye color, skin
pigmentation and skin cancer (in GRM5 and TYR,
Tables S14).
For the locus-based view, we conducted a phenome-
wide association study (PheWAS): we evaluated whether
the two lead variants were associated with any of the
778 traits in UK Biobank using GeneAtlas (n = 452,264,
age-adjusted estimates; Table S15) [42]. For the CD46
lead variant, we identified 27 significant trait associations
(FDR < 5%), including four with particularly strong evi-
dence (P < 5.0 × 10− 8; white blood cell, neutrophil,
monocyte count and plateletcrit); the early AMD risk in-
creasing allele (G, frequency = 79%) was associated con-
sistently with increased blood cell counts. We did not
find a significant association of the CD46 lead variant
with schizophrenia in UK Biobank (FDR > 5%; Alzhei-
mer’s disease not available). For the TYR lead variant
(rs621313, G allele associated with increased early AMD
risk, frequency = 48%), we identified 20 significant trait
associations including Melanoma (FDR < 5%, G allele as-
sociated with increased Melanoma risk) and two with
particularly strong evidence for skin color and ease of
Table 3 Summary of in silico follow-up and gene prioritization score (GPS)
Annotation for variants in 95%
credible set
Biology of the gene
Locus Candidate
gene















CD46 CD46 1 207,925,382 207,968,861 11 4 0 0 1 1 1 1 0
CD46 CR1L 1 207,818,457 207,897,036 1 1 0 0 0 0 0 1 0
CD46 PLXNA2 1 208,195,587 208,417,665 0 2 0 0 0 0 1 1 0
CD46 CR1 1 207,669,472 207,815,110 0 2 0 0 0 0 1 1 0
CD46 LOC148696 1 207,991,723 207,995,941 1 0 0 0 0 NA NA 0 0
CD46 CD34 1 208,059,882 208,084,683 0 1 0 0 0 0 1 0 0
CD46 CD55 1 207,494,816 207,534,311 0 1 0 0 0 0 1 0 0
CD46 CR2 1 207,627,644 207,663,240 0 0 0 0 0 0 0 0 0
CD46 MIR29B2 1 207,975,787 207,975,868 0 0 0 0 0 NA NA 0 0
CD46 MIR29C 1 207,975,196 207,975,284 0 0 0 0 0 NA NA 0 0
TYR TYR 11 88,911,039 89,028,927 39 4 1 0 0 0 1 1 1
TYR NOX4 11 89,057,521 89,322,779 1 3 0 1 1 0 1 0 0
TYR GRM5 11 88,237,743 88,796,846 109 1 0 0 0 0 1 0 0
TYR FOLH1B 11 89,392,464 89,431,886 0 0 0 0 0 0 0 0 0
TYR GRM5-AS1 11 88,237,743 88,257,222 0 0 0 0 0 0 NA 0 0
TYR TRIM49 11 89,530,822 89,541,743 0 0 0 0 0 0 NA 0 0
TYR TRIM77 11 89,443,466 89,451,040 0 0 0 0 0 0 NA 0 0
a Variants in 95% credible set are a local expression quantitative trait locus for this gene in retina (EyeGEx) or any tissue included in the GTEx database (cis for
genes in locus); § Expression in Eye Integration data; NMD nonsense-mediated mRNA decay; OMIM Online Mendelian Inheritance in Man (https://www.omim.org/);
NA data not available; The gene start and end positions were extracted from the hg19 gene range list from http://www.cog-genomics.org/plink/1.9/resources
The table summarizes statistical and functional evidence for 10 and seven candidate genes of the novel early AMD loci on chromosome 1 and chromosome 11,
respectively. Detailed results on the individual statistical and functional analyses are shown in Tables S6-S12. For the GPS, the sum of cell entries for “annotation”
and “biology” was computed per row
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skin tanning (P < 5.0 × 10− 8, G allele associated with
brighter skin color and increased ease of skin tanning).
Advanced AMD association and interaction analyses for
the two novel loci
Next, we investigated whether the early AMD loci CD46
or TYR were associated with advanced AMD. We thus
queried the two lead variants for early AMD (rs4844620
and rs621313, respectively) for their advanced AMD asso-
ciation in the IAMDGC data (Table S16). We observed
nominally significant directionally consistent effects for
advanced AMD (ORadv = 1.05, 95% confidence interval,
CI = [1.01,1.09] and 1.03 [1.00,1.07], Padv = 0.02 and 0.05,
respectively) that were slightly smaller compared to early
AMD effects (ORearly = 1.10 [1.06,1.14] and 1.05 [1.02,
1.08], Pearly = 4.7 × 10
− 8 and 6.8 × 10− 4).
When exploring variant x age interaction for early
AMD (in a subset of our meta-analysis of 10,890 early
AMD cases and 54,697 controls) or for advanced AMD
(IAMDGC data [44]) for the two novel locus lead vari-
ants, we found no statistically significant interaction at a
Bonferroni-corrected level for early or advanced AMD
(PGxAGE > 0.05/2 = 0.025, Table S17-S18).
We were interested in whether one of the two novel
lead variants showed interaction with any of the 34
known advanced AMD variants for association with
advanced AMD (IAMDGC data). We found no signifi-
cant interaction (PGxG > 0.05/34/2, Table S19), which
suggests that the known advanced AMD effects are not
modulated by the two novel early AMD variants.
Dissecting advanced AMD genetics into shared and
distinct genetics for early AMD
We were interested in whether we could learn about ad-
vanced AMD genetics from a joint view of advanced and
early AMD genetic effects. First, when computing genetic
correlation of advanced AMD genetics with early AMD
genetics, we found a substantial correlation of 78.8%
(based on LD-score regression). Second, we contrasted ad-
vanced AMD effect sizes (IAMDGC data [9]) with early
AMD effect sizes (our meta-analysis,) for the 34 known
advanced AMD lead variants (Fig. 2, Table S16). We
found two classes of variants: (1) 25 variants showed nom-
inally significant effects on early AMD (P < 0.05; “ad-
vanced-and-early-AMD loci”), all directionally consistent
and all smaller for early vs. advanced AMD (ORearly =
1.04–1.47; ORadv = 1.10–2.81); (2) nine variants had no
nominally significant effect on early AMD (P ≥ 0.05; “ad-
vanced-only AMD loci”). We did not find any variant with
early AMD effects into the opposite direction as the ad-
vanced AMD effects. Also, we did not find any variant-age
interaction on early AMD (Table S18).
Fig. 2 Advanced vs early AMD effect sizes. Shown are advanced AMD effect sizes contrasted to early AMD effect sizes (effect sizes as log odds
ratios) for the 34 known advanced AMD variants [9] (blue or green for Pearly < 0.05 or Pearly ≥ 0.05, respectively) and for the two novel (early) AMD
variants (red, near CD46, TYR). Detailed results are shown in Table S16
Winkler et al. BMC Medical Genomics          (2020) 13:120 Page 11 of 18
We observed that complement genes CFH, CFI, C3,
C9, and C2 were all included in the 25 advanced-and-
early-AMD loci. We were thus interested in whether
advanced-and-early-AMD loci suggested different path-
ways compared to advanced-only-AMD loci. For this, we
utilized the GPS from our previous work on advanced
AMD [9] to select the best-supported genes in each of
these loci (Table S20). We applied Reactome pathway
analyses via Enrichr [47] twice: (i) for the 35 genes in
the 25 advanced-and-early-AMD loci and (ii) for the
nine genes in eight advanced-only-AMD loci (no gene in
the “narrow” locus definition of the RORB locus). This
revealed significant enrichment (corrected P < 0.05) for
genes from “complement system” and “lipoprotein me-
tabolism” in the 25 advanced-and-early-AMD loci and
enrichment for genes in the pathways “extracellular
matrix organization” and “assembly of collagen fibrils” in
the 8 advanced-only-AMD loci (Table 4). This suggested
that the early AMD effect of advanced AMD variants
distinguished the major known pathways for advanced
AMD.
Discussion
Based on the largest genome-wide meta-analysis for
early AMD to date encompassing ~ 14,000 cases and ~
91,000 controls, all color fundus photography confirmed
and a candidate approach based on 14 suggestive vari-
ants from Holliday et al. [12], we identified 10 loci for
early AMD including eight novel and two previously
identified for early AMD [12]. Eight of the 10 identified
loci overlapped with known loci for advanced AMD [9]
and two had not been detected by GWAS for early or
advanced AMD so far. Our post-GWAS approach
highlighted CD46 and TYR as compelling candidate
genes in the two loci. Our joint view on early and ad-
vanced AMD genetics allowed us to differentiate be-
tween shared and distinct genetics for these two disease
stages, which the pathway analyses suggested to be bio-
logically relevant.
We defined three tiers of identified variants that
reflected the different levels of data and evidence: tier 1
variants were identified with genome-wide significance
in our GWAS meta-analysis data (identifying 8 loci in-
cluding CD46), tier 2 variants were among the 14
candidate-based variants judged at experiment-wise sig-
nificance in our non-overlapping data (P < 0.05/14 =
0.0036) as well as at genome-wide significance in the
combined analysis (i.e. previously published summary
statistics and ours; identifying one additional locus near
APOE), and tier 3 variants were among the 14 variants
judged at experiment-wise significance, but no genome-
wide significance in the combined data (identifying one
additional locus near TYR). While the establishing of
genome-wide significance for a locus is ideal, testing at a
statistical significance level controlling the experiment-
wise type 1 error with Bonferroni-correction is also an
established approach to provide statistical evidence in
independent data [48].
Particularly interesting were the two loci near CD46
and TYR that were identified here for early AMD with
statistical significance and have not been identified pre-
viously, not even for advanced AMD. The locus around
CD46 had been reported as suggestive for early AMD by
the previous largest GWAS for early AMD [12] (4089
early AMD cases, 20,453 controls), but not with statis-
tical significance, and had not been identified with statis-
tical significance by the previous largest GWAS for
advanced AMD [9] (16,144 advanced AMD cases, 17,832
Table 4 Enriched pathways




Raw P Corrected P Genes contributing to
enrichment
Effects on early and
advanced AMD
Regulation of Complement cascade
(R-HSA-977606)
26 5 7.8 × 10−10 1.2 × 10−6 C3;CFH;C9;CFI;CFB
Lipoprotein metabolism (R-HSA-174824) 34 4 3.5 × 10−7 1.8 × 10−4 ABCA1;CETP;LIPC;APOE
Complement cascade (R-HSA-166658) 80 5 2.7 × 10−7 2.0 × 10−4 C3;CFH;C9;CFI;CFB
HDL-mediated lipid transport (R-HSA-194223) 19 3 4.7 × 10− 6 1.8 × 10−3 ABCA1;CETP;APOE
Lipid digestion, mobilization, and transport
(R-HSA-73923)
71 4 7.0 × 10− 6 2.2 × 10− 3 ABCA1;CETP;LIPC;APOE
Activation of C3 and C5 (R-HSA-174577) 6 2 4.4 × 10−5 0.011 C3;CFB
no effects on early
AMD
Assembly of collagen fibrils and other
multimeric structures (R-HSA-2022090)
54 3 1.5 × 10− 6 2.4 × 10−3 COL15A1;COL8A1;MMP9
Collagen formation (R-HSA-1474290) 85 3 6.1 × 10− 6 3.1 × 10− 3 COL15A1;COL8A1;MMP9
Extracellular matrix organization
(R-HSA-1474244)
283 4 4.7 × 10− 6 3.6 × 10− 3 VTN;COL15A1;COL8A1;MMP9
The table shows enriched pathways for highest prioritized genes (from Fritsche et al. 2016 without modifications) in the 25 late AMD loci with early AMD effects
(35 genes) versus the 8 loci with no effect on early AMD (9 genes). Pathways with significant corrected P-value (Pcorr < 0.05) for each gene group from EnrichR
querying human Reactome database 2016 are shown
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controls). Our meta-analysis was more than three times
larger than the previous early AMD GWAS (effective
sample size 48,651 compared to 13,631 [12]) and had a
larger power to detect an “any AMD” effect with
genome-wide significance than the previous advanced
AMD GWAS (e.g. for OR = 1.10, allele frequency 30%:
power = 92% compared to 61%, respectively). The TYR
locus had not been identified with statistical significance
in any previous GWAS on early or advanced AMD; it
was stated as a locus with suggestive evidence from the
previous GWAS on early AMD (P = 3.5 × 10− 6) [12] and
was identified here with statistical significance at
experiment-wise error control. The combined analysis of
the Holliday et al. and our non-overlapping data clearly
separated the 14 Holliday variants into four with
genome-wide or close to genome-wide significance and
10 that were far away from statistical significance.
Prioritization of genes underneath association signals
is a known challenge, but highly relevant for selecting
promising candidates for functional follow-up. Our sys-
tematic approach, scrutinizing all genes underneath our
two newly identified loci, highlighted CD46 and TYR as
the most supported genes. CD46 is an immediate com-
pelling candidate as a part of the complement system
[49]. Complement activation in retina is thought to have
a causal role for AMD [50, 51]. Importantly, we found
our CD46 GWAS signal to colocalize with CD46 expres-
sion with the early AMD risk increasing allele
(rs4844620 G) increasing CD46 expression in retinal
cells. On the one hand, this contrasts the presumption
that a higher CD46 expression in eye tissue should pro-
tect from AMD, based on previous CD46 expression
data [52] and a documented AMD risk increasing effect
for increased complement inhibition [53]. On the other
hand, CD46 had also been found to have pathogenic re-
ceptor properties for human viral and bacterial patho-
gens (e.g. measles virus) [54] and is known to down-
modulate adaptive T helper type 1 cells [55]. Further-
more, a GWAS on neutralizing antibody response to
measles vaccine had identified two intronic CD46 vari-
ants (rs2724384, rs2724374) [56]. In our data, these two
variants were in the 95% credible set for the CD46 locus,
highly correlated with our lead variant rs4844620 (r2 > =
0.95), and the major alleles (rs2724374 T, rs2724384 A)
increased early AMD risk. Interestingly, the rs2724374 G
was shown for CD46 exon skipping resulting in a shorter
CD46 isoform with a potential role in pathogen binding
[56]. Based on this, one may hypothesize that the ob-
served CD46 signal in early AMD is related to patho-
genic receptor properties rather than complement
inactivation.
At the second locus, TYR appears as the best supported
gene by our systematic scoring. This locus and gene was
already discussed by Holliday and colleagues [12]. Briefly,
TYR is important for melanin production and TYR vari-
ants in human were associated with skin, eye and hair
color [57–59]. While we did not identify any cis effect be-
tween the credible set variants and TYR expression, one of
our credible set variants in TYR (rs1042602) is a missense
variant. Interestingly, this variant was a GWAS lead vari-
ant not only for skin color [58], but also for macular thick-
ness in UK Biobank [60]; the allele associated with thicker
retina showed increased early AMD risk in our data. Since
thicker RPE/Bruch’s membrane complex was associated
with increased early AMD risk in the AugUR study [61],
this would be in line with our early AMD risk increasing
allele being linked to a process of increased accumulation
of drusenoid debris in the RPE/Bruch’s membrane com-
plex. Although CD46 and TYR were the most supported
genes in the two loci, we could not rule-out the relevance
of other genes in the loci.
It is a strength of the current study that early AMD
and control status was ascertained by color fundus pho-
tography, not relying on health record data. However,
the early AMD classification in our GWAS was hetero-
geneous across the 11 data sets: one study incorporated
information from optical coherence tomography (NIC-
OLA), the UK Biobank classification was derived by a
machine-learning algorithm [20], and the IAMDGC data
was multi-site with different classification approaches
[9]. The uncertainty in early AMD classification and the
substantial effort required for any manual AMD classifi-
cation are likely reasons for the sparsity of early AMD
GWAS so far. Our sensitivity analysis with the leave-
one-out meta-analyses and corresponding heterogeneity
estimates showed that effect estimates did not depend
on one or the other data source or classification
approach.
Our data on early AMD genetics is comparable in size
to the existing data on advanced AMD genetics from
IAMDGC (summary statistics at http://amdgenetics.org/
) and thus provides an important resource (summary
statistics at http://genepi-regensburg.de) to enable a joint
view. By this joint view, we were able to differentiate the
34 loci known for advanced AMD into 25 “advanced-
and-early-AMD loci” and nine “advanced-AMD-only
loci”. Pathway enrichment analyses conducted separately
for these two groups effectively discriminated the major
known pathways for advanced AMD genetics [9]: com-
plement complex and lipid metabolism for “advanced-
and-early-AMD” loci; extracellular matrix metabolism
for “advanced-AMD-only” loci. The two novel loci
around CD46 and TYR fit to the definition of “ad-
vanced-and-early-AMD” loci and the CD46 being part of
the complement system supports the above stated path-
way pattern. The larger effect size for early compared to
advanced AMD for the two novel loci may – in part –
be winner’s curse.
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How do our observations relate to potential etiological
models? (1) For a genetic variant capturing an under-
lying mechanism that triggers both early and advanced
AMD, we would expect the variant to show association
with early and advanced AMD (compared to “healthy”)
with directionally consistent effects (Fig. 3, Model 1).
This would be in line with our observed associations for
the 27 “advanced-and-early-AMD” loci (25 known ad-
vanced AMD loci, 2 novel loci). This would also suggest
that mechanisms of complement system or lipid metab-
olism trigger both early and advanced disease. (2) For a
mechanism that triggers advanced AMD no matter
whether the person is “healthy” or has early AMD, we
would anticipate a variant effect for advanced AMD, but
not for early AMD (Fig. 3, Model 2). This would be in
line with our observed associations for the nine “ad-
vanced-AMD-only” loci. This would also suggest that
mechanisms of extracellular matrix metabolism trigger
advanced AMD rather than early AMD. Of note, these
include the MMP9 locus, which is thought to trigger
vascularization and wet AMD [9]. (3) Another mechan-
ism is conferred by variants that are purely responsible
for progression from early to advanced AMD, but do
not increase advanced AMD risk for “healthy” individ-
uals. In such a scenario, the advanced AMD risk increas-
ing allele would be under-represented among persons
with early AMD (Fig. 3, Model 3), particularly at older
age, and it would be associated with decreased risk of
early AMD (compared to “healthy”). None of the identi-
fied variants showed this pattern overall or for older age
in the variant x age interaction analyses. (4) For a mech-
anism that triggers early AMD, but has no impact on
the progression from early to advanced AMD, we would
have an effect on early AMD, but no effect on advanced
AMD (Fig. 3, Model 4). We did not find such a variant.
Our data and joint view on effects for both disease
stages support two of the four etiological models. One
may hypothesize that the unsupported models are non-
existing or unlikely. There are limitations to consider:
(1) To reduce complexity, we adopted an isolated view
per variant with some accounting for interaction, but ig-
noring more complex networks. (2) Early AMD effects
were estimated predominantly in population-based stud-
ies, while advanced AMD effects were from a case-
control design. (3) The cut-off of “nominal significance”
for separating variants into “advanced-and-early” or “ad-
vanced-only” loci is arbitrary and larger data might give
rise to re-classification. Still, the power to detect effects
for early AMD in our meta-analysis was similar to the
power in the advanced AMD data from IAMDGC (for
OR = 1.05, allele frequency 30%, nominal significance:
power = 94% or 83%, respectively). (4) An improved dis-
entangling of genetic effects for the two chronologically
linked disease stages will be an important subject of fur-
ther research, requiring large-scale population-based
studies with long-term follow-up and the estimation of
transition probabilities.
Conclusions
In summary, our large GWAS on early AMD identified
novel loci, highlighted shared and distinct genetics be-
tween early and advanced AMD and provides insights
into AMD etiology. The ability of early AMD effects to
differentiate the major pathways for advanced AMD un-
derscores the biological relevance of a joint view on early
and advanced AMD genetics.
Fig. 3 Etiological models and the respective expected association of a variant with early and advanced AMD
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